CONTEPO (Fosfomycin Disodium) Patent Expiration, LOE Window & CMS Spending

CONTEPO (Fosfomycin Disodium) by Meitheal: FDA Orange Book LOE 2039-01-30, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $2,193 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMeitheal
FDA Application & PathwayN212271 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-01-30
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,193 intro WAC)